

## Correspondence

### Evaluation of antibiotic & antibiotic modifying activity of pilocarpine & rutin

Sir,

Secondary metabolites are small molecules<sup>1</sup>, responsible for various biological activities, acting as antibiotic, antifungal and antiviral agents to protect plants from pathogens. There are large groups of secondary metabolites, which include alkaloids and flavonoids<sup>2</sup>, described mainly by their antimicrobial<sup>3,4</sup> and antioxidant potential<sup>5</sup>. Pilocarpine is an alkaloid present in the leaves of jaborandi (*Pilocarpus microphyllus*)<sup>6</sup>, which is utilized as a phytotherapeutic agent in the treatment of glaucoma and xerostomia<sup>7</sup>. Rutin is a flavonoid belonging to the subclass of flavones found in various plant sources<sup>8,9</sup>, which has shown antioxidant activity<sup>10</sup>, efficacy in the control of *Aspergillus ochraceus*<sup>11</sup>, anticonvulsant effects in rats<sup>12</sup>, suppression of cellular immunity<sup>13</sup>, anticarcinogenic activity<sup>14</sup> and antiinflammatory effect<sup>15</sup>. The irrational use of antibiotics and antifungals has resulted in the development of drug resistance. The rapid development of drug resistance and the slow-down in the development of new active drugs, have drawn attention to treatment with drug combinations<sup>16</sup>. The aim of this study was to evaluate the antibacterial and antifungal activity of rutin and pilocarpine and to determine their possible modifying effect when combined with aminoglycoside antibacterials and the antifungal amphotericin B.

The experiments were carried out in Laboratory of Microbiology and Molecular Biology, Department of Biological Chemistry, Regional University of Cariri, Crato, Brazil, with standard and multiresistant strains of *Staphylococcus aureus* and *Escherichia coli*: *S. aureus* ATCC 12692, *S. aureus* 358 (MRSA), *E. coli* ATCC 25922 and *E. coli* 27 (EC27). All strains were maintained on heart infusion agar slants (HIA; Difco, USA), and before the assays, the cells were grown in brain heart infusion broth (BHI; Difco) for

24 h at 37°C. Clinical isolate EC27 was resistant to neomycin and gentamicin (low level) and to amikacin and kanamycin<sup>17</sup>. *S. aureus* 358 (MRSA) showed resistance to methicillin. All strains were obtained from the collection of microorganisms of the Mycology Laboratory, UFPB, Paraiba, Brazil. Three standard yeast strains were utilized: *Candida albicans* ATCC 40227, *C. krusei* ATCC 6538 and *C. tropicalis* ATCC 13803. All these strains were maintained on HIA, and before the assays, the cells were grown in BHI for 24 h at 37°C. The antibiotics tested were the aminoglycosides amikacin, kanamycin, gentamicin and neomycin (Sigma, USA). The antifungal agent was amphotericin B (Sigma, USA). The antibiotic and antifungal solutions were prepared following the recommendations of the Clinical and Laboratory Standards Institute – CLSI<sup>18</sup>. The test compounds (pilocarpine and rutin) (obtained from Merck & Company, Germany), was dissolved (10 mg) in 1 ml dimethylsulphoxide (DMSO- Merck, Darmstadt, Germany), giving an initial concentration of 10 mg/ml. Starting with this concentration, a dilution was made to 1024 µg/ml,

**Table I.** Evaluation of antifungal and antibacterial activities of test compounds

Cepas	Minimal inhibitory concentration - MIC (µg/ml)		
	Rutin	Pilocarpine	Negative DMSO control
<i>C. albicans</i> (ATCC 40227)	32	32	32
<i>C. krusei</i> (ATCC6538)	32	32	32
<i>C. tropicalis</i> (ATCC 13803)	32	32	32
<i>E. coli</i> 27	128	128	128
<i>E. coli</i> (ATCC 10536)	128	128	128
<i>S. aureus</i> 358	128	128	128
<i>S. aureus</i> (ATCC 25923)	128	128	128

**Table II.** Evaluation of antibiotic modifying activity of test compounds

	Concentrations ( $\mu\text{g/ml}$ )							
	<i>S. aureus</i> 358				<i>E. coli</i> 27			
	AMI	KAN	GEN	NEO	AMI	KAN	GEN	NEO
Rutin	156.25	2.500	19.53	312.5	156.25	312.5	19.53	156.25
Pilocarpine	156.25	2.500	$\leq 1.22$	39.06	156.25	312.5	19.53	156.25
DMSO	156.25	2.500	19.53	312.5	156.25	312.5	19.53	156.25
C+	156.25	2.500	19.53	312.5	156.25	312.5	19.53	156.25
C+, only antibiotic								

and further dilutions were made serially 1:2 in culture medium, obtaining concentrations of 512 to 8  $\mu\text{g/ml}$ . The minimal inhibitory concentration (MIC,  $\mu\text{g/ml}$ ) was determined in 10 per cent BHI by the broth microdilution method, using a suspension of  $10^5$  cfu/ml and a drug concentration of 1024-1  $\mu\text{g/ml}$ <sup>19</sup>. To evaluate the test compounds for drug modifying activity when combined with antibiotics and antifungals, a subinhibitory concentration was determined as the MIC/8 values of 16  $\mu\text{g/ml}$  for EC27 and MRSA, and 10  $\mu\text{g/ml}$  for *C. albicans*, *C. krusei* and *C. tropicalis*. The plates were incubated for 24 h at 37 °C, utilizing resazurin to read bacterial growth and no stain for fungi.

The MIC values for rutin and pilocarpine showed no antibacterial or antifungal activity against the strains tested (Table I). Pilocarpine, however, increased bacterial sensitivity to the aminoglycosides gentamicin and neomycin, when added concomitantly (Table II). Pilocarpine combined with these aminoglycosides altered synergistically the MIC values against *S. aureus* but not *E. coli*. Neither of the compounds tested showed an antifungal modifying effect ( $> 1024$   $\mu\text{g/ml}$ ) with amphotericin B against the *Candida* strains tested.

The MIC values determined in the antifungal and antibacterial assays were equal to that of the negative DMSO control, suggesting that this activity was due to DMSO which is considered toxic only at higher concentration<sup>20</sup>. Rutin has been extensively studied for its various pharmacological properties, such as its anti-candida activity<sup>9,21</sup>. Missau *et al*<sup>22</sup> used the direct bioautography method and showed anti-fungal activity against three strains of *Candida*, with a significant effect against only *C. krusei*. Bolle *et al*<sup>23</sup> found that this method could result in decomposition of the test substances during the assay. Our findings corroborated with that of Pereira *et al*<sup>11</sup> who showed that rutin, isolated from the plant species *Solanum palinacanthum*

does not inhibit the growth of *Staphylococcus aureus*. The use of drugs in combination has been extensively studied, mainly because of the emergence of resistant strains<sup>24</sup>.

The synergistic effect of pilocarpine indicates a new therapeutic possibility for the treatment of diseases associated with *S. aureus* infection and an alternative for the resistance shown by this microorganism against certain aminoglycosides. Further studies are required to evaluate the toxicity and antibacterial activity of this compound *in vivo*.

**Competing interests:** The authors declare that they have no competing interests.

**Mariana K.A. Araruna<sup>\*,†</sup>, Samara A. Brito<sup>\*\*</sup>,  
Maria F.B. Morais-Braga<sup>†</sup>, Karla K.A. Santos<sup>†</sup>,  
Teogenes M. Souza<sup>†</sup>, Tiago R. Leite<sup>††</sup>**

**Jose G.M. Costa<sup>\*\*</sup> & Henrique D.M. Coutinho<sup>†</sup>**

<sup>\*</sup>Laboratório de Farmacologia e Química Molecular (LFQM), <sup>\*\*</sup>Laboratório de Pesquisa de Produtos Naturais (LPPN), <sup>†</sup>Laboratório de Microbiologia e Biologia Molecular (LMBM), <sup>††</sup> Laboratório de Botânica Aplicada (LBA), Universidade Regional do Cariri – URCA, Crato, Ceara, Brazil

<sup>†</sup>For correspondence:

Universidade Regional do Cariri, Departamento de Química Biológica, Crato, CE, Brazil. Av. Cel. Antônio Luiz N° 1161, Cep:63105-000  
marianakessia@yahoo.com.br

## References

1. Salisbury FB, Ross CW. *Plant physiology*, 4<sup>th</sup> ed. Belmont: Wadsworth Publishing Company; 1992. p. 681.
2. Simões CMO, Schenkel EP, Gosmann G, de Mello JCP, Mentz LA, Petrovick PR. *Farmacognosia: da planta ao medicamento*, 6<sup>th</sup> ed. Editora da UFRGS; Florianópolis: Editora da UFSC; 2007. p. 1104.
3. Djipa CD, Delmee M, Quentin-Leclercq J. Antimicrobial activity of bark extracts of *Syzygium jambos* (Myrtaceae). *J Ethnopharmacol* 2000; 71 : 307-13.

4. Esquenazi D, Wigg MD, Miranda MM, Rodrigues HM, Tostes JB, Rozental S, *et al.* Antimicrobial and antiviral activities of polyphenolics from *Cocos nucifera* Linn. (Palmae) husk fiber extract. *Res Microbiol* 2002; 52 : 647-52.
5. Barreiros ALBS, David JM. Oxidative stress: Relation between the formation of reactive species and the organism's defense. *Química Nova* 2006; 29 : 113-23.
6. Pinheiro CUB. Extractivism, cultivation and privatization of jaborandi (*Pilocarpus Microphyllus* Stapf Ex Holm., *Rutaceae*) in Maranhão, Brazil. *Acta Bot Brás* 2002; 6 : 141-50.
7. <http://www.abiquif.org.br/PDFs/mercado.pdf>, accessed on April 27, 2010.
8. Oliveira A, Silva B. Marmelo (*Cydonia oblonga* Miller): Source of biologically active compounds. *Revista da Faculdade de Ciências da Saúde* 2007; 4 : 78-84.
9. Pedriali, CA. The chemical synthesis of water-soluble derivatives of rutin: determination of its physico-chemical properties and evaluation of its antioxidants activities dissertation. São Paulo (SP): *Universidade de São Paulo*; 2005.
10. Afanas'EV JB, Dorozhko AJ, Brodskill AV, Kostyuk VA, Patapovitch AI. Chelating and free radical scavenging mechanisms of inhibitory action of rutin and quercetin in lipid peroxidation. *Biochem Pharmacol* 1989; 38 : 1763-9.
11. Pereira AC, Oliveira DF, Geraldo H, Silva GH, Figueiredo HCP, Cavalheiro AJ, *et al.* Identification of the antimicrobial substances produced by *Solanum palinacanthum* (*Solanaceae*). *Ann Brazilian Acad Sci* 2008; 80 : 427-32.
12. Nassiri-als M, Shariati-rad S, Zamansoltan F. Anticonvulsive effects of intracerebroventricular administration of rutin in rats. *Prog Neuro-Psychopharmacol Biol Psychiatry* 2008; 32 : 989-93.
13. Middleton EJR, Kandaswam C, Theoharides TC. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease and cancer. *Pharmacol Rev* 2000; 53 : 673-751.
14. Machado H. *Effect the flavonoids rutin and naringin on the Ehrlich ascetic tumor "in vivo"*. Thesis (Master) – Programa de Pós-Graduação em Bioquímica Agrícola, Universidade Federal de Viçosa, Viçosa-MG 2005.
15. Guardia T, Rotelli AE, Juarez AQ, Pelzer LE. Anti-inflammatory properties of plant flavonoids. Effect of rutin, quercetin and hiperidin on adjuvant arthritis in rat. *Pharmacology* 2001; 56 : 683-7.
16. Keith CT, Borisy AA, Stockwell BR. Multicomponent therapeutics for networked systems. *Nat Rev Drug Discovery* 2005; 4 : 71-8.
17. Coutinho HDM, Cordeiro LN, Bringel KP. Antibiotic resistance of pathogenic bacteria isolated from the population of Juazeiro do Norte-Ceara. *R Bras Ci Saúde* 2005; 9 : 127-38.
18. CLSI. National committee for clinical laboratory standards. *Performance standards of antimicrobial disk susceptibility test*, 8<sup>th</sup> ed. Atlanta, USA: CLSI; 2003. p. 2-8.
19. Javadpour MM, Juban MM, Lo WC, Bishop SM, Alberty JB, Cowell SM, *et al.* *De novo* antimicrobial peptides with low mammalian cell toxicity. *J Med Chem* 1996; 39 : 3107-13.
20. Brayton CF. Dimethyl sulfoxide (DMSO): a review. *Cornell Vet* 1986; 76 : 61-90.
21. Han Y. Rutin has therapeutic effect on septic arthritis caused by *Candida albicans*. *Int Immunopharmacol* 2009; 9 : 207-11.
22. Johann S, Mendes BG, Missau FC, Rezende MA, Pizzollati MG. Antifungal activity of five species of *Polygala*. *Brazilian J Microbiol* 2011; 42 : 1065-75.
23. Bolle MFC, Goderis IJ, Terras FRG, Cammue BPA, Broekaert WF. A technique for detecting antifungal activity of proteins separated by polyacrylamide gel electrophoresis. *Electrophoresis* 1991; 12 : 442-4.
24. Rastogi N. Antimycobacterial activity of chemically defined natural substances from the caribbean flora in guadaloupe. *FEMS Immunol Medical Microbiology* 1998; 20 : 267-73.